IP Verse

Therapeutic Combinations Of A Btk Inhibitor, A Pi3K Inhibitor, A Jak-2 Inhibitor, And/Or A Bcl-2 Inhibitor

Patent No. EP3179991 (titled "Therapeutic Combinations Of A Btk Inhibitor, A Pi3K Inhibitor, A Jak-2 Inhibitor, And/Or A Bcl-2 Inhibitor") was filed by Acerta Pharma on Aug 11, 2015. The application was issued on Oct 6, 2021.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
STADA ARZNEIMITTELJul 5, 2022HAMM & WITTKOPP

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3179991

ACERTA PHARMA
Application Number
EP15757002A
Filing Date
Aug 11, 2015
Status
Granted And Under Opposition
Sep 3, 2021
Publication Date
Oct 6, 2021
External Links
Slate, Register , Google Patents